Almost every clinical trial excludes pregnant women, which means the evidence about medicines in pregnancy is built largely from observation after the fact - registries, cohort studies and individual reports. That makes a report from someone who took a medicine during pregnancy unusually valuable, and it is the main reason this is worth doing even when nothing seems to have gone wrong.
What to report, and when
Report a suspected side effect in yourself, in the pregnancy, or in the baby.
That includes effects appearing at the time, and things noticed later - a problem at birth, or in a child's development, where a medicine taken during pregnancy is a possibility.
You do not need to be sure the medicine was responsible. The threshold is suspicion, and the guidance is explicitly to report if in doubt.
Anyone can report - the woman herself, a partner, a parent or a health professional.
See how the Yellow Card scheme works.
What makes a report useful
The details that let a report contribute to a pattern:
- Which medicine, by generic name, and the brand if known
- When in the pregnancy it was taken - which trimester, and ideally which weeks. Timing matters enormously, since different structures form at different points
- How long it was taken for
- Everything else taken at the same time, including over-the-counter medicines and supplements
- Other conditions, since the underlying illness may itself be relevant
- What happened, and when it was noticed
The batch number is worth including for vaccines and biologics.
See keeping a side effect diary.
Exposure before you knew
A very common situation, and one worth reporting even when the outcome is entirely normal.
Many pregnancies are confirmed after the first few weeks, by which point a medicine may have been taken throughout the period when organs are forming.
Reports of normal outcomes after exposure are as valuable as reports of problems - without them, the record contains only the bad news and the risk looks larger than it is.
If this has happened to you, the immediate step is advice rather than panic: do not stop a medicine abruptly, and seek advice the same week. For epilepsy, serious mental illness, asthma, diabetes and transplant, stopping is considerably more dangerous than continuing.
See getting the right medicine in pregnancy.
Pregnancy registers
Alongside Yellow Card, specific registers collect information on particular medicines in pregnancy - anti-epileptics being the longest established, and the source of what is now known about valproate.
Some biologics and newer medicines have their own registers, usually run by the manufacturer under a regulatory requirement.
If you are taking one of these, ask whether there is a register you can enrol in. It is voluntary, and it is how the next generation gets better information than you had.
Where to get information, as opposed to reporting
Reporting contributes to the evidence. Getting advice for yourself is a different task.
The UK Teratology Information Service produces evidence summaries written for patients through its bumps website, and clinicians can telephone the service for individual advice on a specific exposure.
That is a far better source than a leaflet, which is written defensively and typically says only that the medicine should not be used unless clearly necessary.
Specialist midwives, obstetric physicians and perinatal mental health teams exist for exactly these questions - ask to be referred rather than deciding alone.
Avoid forums, which are frequently alarming and frequently wrong.
Breastfeeding
Report suspected effects in a breastfed baby too - unusual drowsiness, poor feeding, irritability or a rash appearing after a medicine was started.
The picture here is generally more reassuring than for pregnancy: most medicines transfer into milk in very small amounts, and a great many are compatible with breastfeeding.
The commonest error is stopping breastfeeding unnecessarily on the strength of a leaflet, when a specialist source would have said it was fine.
See antidepressants in pregnancy.
Fathers and the months before conception
Reporting is not only about medicines taken by the mother.
A few medicines taken by a male partner around conception carry their own requirements, and effects on sperm are far less studied than effects in pregnancy. If a medicine taken by either partner is followed by an unexpected outcome, that is worth reporting with both exposures noted. See medicines and fertility.
Why this matters more than usual
The valproate story is the clearest illustration. The scale of harm in pregnancy took decades to establish, and the delay cost a great deal.
Pregnancy prevention programmes for valproate, topiramate and isotretinoin all exist because of accumulated evidence that began with individual reports.
Under-reporting is the scheme's main limitation, and it is worst in exactly the situations where evidence is thinnest.
See topiramate and side effects in children.
More on side effects and safety in the Side Effects section, including What Happens After You Report.